Page 24 - ANTIFUNGAL SUSCEPTIBILITY OF CLINICAL YEAST ISOLATES 2018-2020

7. Cryptococcus neoformans complex (C. neoformans complex)

A total of 49 Cryptococcus neoformans complex were analyzed from various

type of clinical specimens. The isolates were from blood (27, 55.1%), CSF (15,
30.6%) and others (7, 14.3%) (Table 7.1). The MIC ranges, MIC50 and MIC90 of

seven (7) antifungals are shown in Table 7.2. There are no validated susceptibility

criteria (clinical breakpoints) provided by CLSI for antifungal agents tested. MICs

provided are for information only.

Table 7.1: Distribution of C. neoformans complex isolated based on clinical
specimens in 2018-2020.

Specimen Type Number
Blood 27 55.1%
CSF 15 30.6%
Others 7 14.3%
Total 49

Table 7.2: MIC50, MIC90 and MIC range values (µg/mL) for C. neoformans complex
in 2018-2020.

Antifungals MIC50 MIC90 MIC Range

Amphotericin B 0.19 0.5 0.001 - 1

Fluconazole 3 16 0.008 - 256

Itraconazole 0.38 1 0.001 – 1.9

Posaconazole * * 0.12 – 0.5

Voriconazole 0.023 0.125 0.004 – 0.38

5-Fluorocytosine 4 32 0.094 - 32

*The number of isolates tested were very low.

24 |